Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUPRENZA vs TEPANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.
TEPANIL (diethylpropion) is a sympathomimetic amine that acts as a norepinephrine reuptake inhibitor in the hypothalamus, increasing norepinephrine levels in the synaptic cleft, which stimulates beta-2 adrenergic receptors, leading to appetite suppression.
Management of moderate to severe chronic pain,Off-label: Treatment of opioid use disorder (as a maintenance therapy similar to buprenorphine)
FDA-approved: Short-term (8-12 weeks) adjunctive therapy for weight management in patients with a body mass index (BMI) ≥30 kg/m² or BMI ≥27 kg/m² in the presence of obesity-related risk factors (e.g., hypertension, diabetes, dyslipidemia). Off-label: None commonly recognized.
Adults: 200 mg orally twice daily with meals.
25 mg orally three times daily, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing for twice-daily dosing.
4-6 hours; clinical context: requires multiple daily dosing for sustained anorectic effect
Primarily hepatic via CYP3A4 and CYP3A5 to norbuprenorphine (active metabolite); also undergoes glucuronidation.
Hepatic metabolism via CYP450 isoenzymes, primarily N-dealkylation and deamination. Active metabolites include N-ethyl- and N,N-diethyl- derivatives.
Approximately 60-80% of a dose is excreted renally as unchanged drug, with 20-40% eliminated via biliary/fecal routes.
Renal: 90% (as metabolites and unchanged drug), Fecal: <10%
Approximately 95-98% bound to plasma proteins, primarily albumin.
30-40% bound to albumin
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume.
3-4 L/kg; indicates extensive tissue distribution
Oral bioavailability is approximately 70-80%.
Oral: 60-70% due to first-pass metabolism
e GFR <45 m L/min/1.73m²: contraindicated. e GFR ≥45: no adjustment.
Contraindicated in end-stage renal disease. For GFR <30 m L/min: not recommended. For GFR 30-59 m L/min: use with caution and monitor for adverse effects.
Child-Pugh Class A: no adjustment; Class B: reduce to 200 mg once daily; Class C: contraindicated.
Contraindicated in severe hepatic impairment. For Child-Pugh Class B: reduce dose by 50% or consider alternative. For Child-Pugh Class A: no adjustment required.
Not recommended for patients under 18 years; safety and efficacy not established.
Not recommended for use in children below 16 years of age due to lack of safety and efficacy data.
No specific dose adjustment; monitor renal function and use caution due to increased risk of adverse effects.
Starting dose of 25 mg once daily in the morning, with slow titration upwards. Monitor for cardiovascular and psychiatric effects due to increased sensitivity.
Risk of respiratory depression, especially in non-opioid-tolerant patients. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of serious injury or death due to accidental exposure in children.
None.
Respiratory depression, particularly in the first 24-72 hours of treatment; caution in patients with pulmonary disease. Risk of QT prolongation. Adrenal insufficiency. Severe hypotension. Risk of misuse, abuse, and addiction. Tolerance and physical dependence.
Pulmonary hypertension: Cases of primary pulmonary hypertension (PPH) have been reported; avoid in patients with known pulmonary hypertension.,Valvular heart disease: Association with regurgitant cardiac valvular disease; avoid in patients with structural cardiac abnormalities.,Serotonin syndrome: Risk when co-administered with serotonergic drugs or MAOIs; allow 14 days after MAOI discontinuation.,CNS stimulation: May cause dizziness, insomnia, and euphoria; avoid with alcohol or other CNS stimulants.,Tolerance/dependence: Tolerance develops with prolonged use; potential for psychological dependence; limit use to 8-12 weeks.,Hypertension: Monitor blood pressure; exacerbate pre-existing hypertension.
Hypersensitivity to buprenorphine or any component of the formulation. Severe respiratory insufficiency. Acute or severe bronchial asthma. Gastrointestinal obstruction, including paralytic ileus.
History of pulmonary hypertension or valvular heart disease.,Hyperthyroidism.,Glaucoma.,Agitated states.,History of drug abuse.,Concurrent use or within 14 days of MAOIs.,Hypersensitivity to diethylpropion or sympathomimetic amines.,Pregnancy and lactation.
No significant food interactions. Grapefruit juice may increase buprenorphine levels; avoid large quantities.
Avoid caffeine, as it may increase stimulant effects and risk of palpitations. Avoid alcohol, which can potentiate CNS effects and increase seizure risk. Take with food if gastrointestinal upset occurs.
Supr ENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: risk of continued virilization, including phallic enlargement and ambiguous genitalia. Fetal growth restriction may occur.
Pregnancy Category X. TEPANIL (diethylpropion) is contraindicated in pregnant women due to anorectic effects potentially causing fetal malnutrition and growth restriction. First trimester exposure may increase risk of neural tube defects, though human data limited. Second and third trimester exposure may lead to reduced birth weight and neonatal withdrawal symptoms including irritability and tremors.
Testosterone is present in breast milk; M/P ratio not reported. Avoid breastfeeding due to potential for androgenization of the infant. Use only if clearly needed and no safer alternative.
Excreted into breast milk; milk-to-plasma ratio not established. Potential for adverse effects in nursing infants including irritability and feeding difficulties. Contraindicated in breastfeeding due to risk of infant exposure and lack of safety data.
Not applicable; Supr ENza is contraindicated in pregnancy. No dose adjustments are recommended as use is avoided entirely.
No dose adjustment is recommended or studied in pregnancy as drug is contraindicated. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism) would likely reduce drug exposure; however, given fetal risks, use is not justified. Avoid use entirely.
SUPRENZA (buprenorphine/naloxone) sublingual film is used for opioid dependence. Monitor for respiratory depression especially when combined with benzodiazepines or alcohol. The naloxone component is poorly absorbed sublingually but precipitates withdrawal if injected. Administer only after clear signs of withdrawal to avoid precipitated withdrawal. Adjust dose in hepatic impairment as buprenorphine is hepatically metabolized.
TEPANIL is a schedule IV controlled substance; assess for history of substance abuse before prescribing. Avoid use in patients with cardiovascular disease, hyperthyroidism, glaucoma, or agitated states. Monitor blood pressure and heart rate regularly. Use only for short-term (8-12 weeks) as tolerance develops. Do not combine with MAOIs or within 14 days of MAOI use. May cause insomnia; advise last dose before 6 PM.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Place film under the tongue until fully dissolved; do not chew or swallow.,Avoid alcohol and benzodiazepines as they can cause severe respiratory depression.,Keep out of reach of children; accidental exposure can be fatal.,Do not abruptly stop; withdrawal symptoms may occur.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose or frequency due to abuse potential.,May cause dizziness or blurred vision; avoid driving until you know how this medicine affects you.,Report chest pain, shortness of breath, or leg swelling immediately.,Avoid alcohol and caffeine-containing products while taking this medication.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Tell your doctor if you have a history of drug abuse or mental health issues.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUPRENZA vs TEPANIL, answered by our medical review team.
SUPRENZA is a Sympathomimetic Anorectic that works by Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.. TEPANIL is a Sympathomimetic anorectic that works by TEPANIL (diethylpropion) is a sympathomimetic amine that acts as a norepinephrine reuptake inhibitor in the hypothalamus, increasing norepinephrine levels in the synaptic cleft, which stimulates beta-2 adrenergic receptors, leading to appetite suppression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUPRENZA and TEPANIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUPRENZA is: Adults: 200 mg orally twice daily with meals.. The standard adult dose of TEPANIL is: 25 mg orally three times daily, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUPRENZA and TEPANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUPRENZA is classified as Category C. SuprENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnorm. TEPANIL is classified as Category C. Pregnancy Category X. TEPANIL (diethylpropion) is contraindicated in pregnant women due to anorectic effects potentially causing fetal malnutrition and growth restriction. First tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.